Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC101 TIL in Advanced NSCLC
NCT06473961Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nolgileucel in non-small cell lung cancer (NSCLC), sponsored by Juncell Therapeutics. Primary endpoints: Adverse Events at 28 days and Objective Response Rate at 18 weeks. Started Oct 2024; status: recruiting.
02
Drugs
nolgileucel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06473961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06473961.